Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.
Divi’s Laboratories experienced a 5% increase in its shares, reaching Rs 11,656, after delivering strong second-quarter results. The pharmaceutical company reported a 64% year-on-year increase in consolidated net profit to Rs 1,127 crore and a 35% increase in revenue from operations to Rs 3,676 crore. Jefferies raised its target price on Divi’s Labs to Rs 12,550 per share from Rs 10,200, citing the company's strong performance in various divisions, including a 50% growth in CDMO business and 18% growth in generics revenue.
The brokerage views Divi’s as the best-in-class CRDMO franchise in its coverage universe, with high long-term growth potential and a pipeline of potential blockbuster products.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
